Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2009 ASCO Annual Meeting

29 May - 2 Jun 2009
United States of America
Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo
Dr Pierre Fouret - Institut Gustave Roussy, France
Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo ( Dr Pierre Fouret - Institut Gustave Roussy, France )
3 Jul 2009
Targeting death receptors in chemo-resistant cancer cells
Prof Patrick Johnston - Queen's University Belfast, UK
Targeting death receptors in chemo-resistant cancer cells ( Prof Patrick Johnston - Queen's University Belfast, UK )
3 Jul 2009
Treatment based on rising CA125 blood levels does not improve survival for recur...
Dr Gordon Rustin - Mount Vernon Cancer Center, UK
Treatment based on rising CA125 blood levels does not improve survival for recurrent ovarian cancer ( Dr Gordon Rustin - Mount Vernon Cancer Center, UK )
3 Jul 2009
Sentinel node biopsy is effective, less invasive option for early-stage cervical...
Dr Fabrice Lecuru - George Pompidou European Hospital, France
Sentinel node biopsy is effective, less invasive option for early-stage cervical cancer patients ( Dr Fabrice Lecuru - George Pompidou European Hospital, France )
3 Jul 2009
Standard treatment plus trastuzumab for HER2+ gastric cancer
Dr Eric Van Cutsem - University Hospital Gasthuisberg, Belgium
Standard treatment plus trastuzumab for HER2+ gastric cancer ( Dr Eric Van Cutsem - University Hospital Gasthuisberg, Belgium )
3 Jul 2009
Olaparib induces tumour response as single agent in BRCA-deficient breast cancer
Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London,...
Olaparib induces tumour response as single agent in BRCA-deficient breast cancer ( Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK )
3 Jul 2009
PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast c...
Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US
PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer ( Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US )
3 Jul 2009
Therapeutic vaccine improves response rate and extends progression-free survival...
Dr Patrick Hwu - M.D. Anderson Cancer Center, US
Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma ( Dr Patrick Hwu - M.D. Anderson Cancer Center, US )
3 Jul 2009
Bortezomib based therapies for myeloma
Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute
Bortezomib based therapies for myeloma ( Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute )
2 Jul 2009
Therapeutic cancer vaccine significantly prolongs disease-free survival for foll...
Dr Stephen Schuster - University of Pennsylvania School of Medicine, USA
Therapeutic cancer vaccine significantly prolongs disease-free survival for follicular lymphoma ( Dr Stephen Schuster - University of Pennsylvania School of Medicine, USA )
2 Jul 2009
PARP inhibitors show promise for hard-to-treat breast cancers
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London...
PARP inhibitors show promise for hard-to-treat breast cancers ( Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK )
25 Jun 2009
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Dr. Jacek Gronwald, International Hereditary Cancer Centre, Poland
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients ( Dr. Jacek Gronwald, International Hereditary Cancer Centre, Poland )
25 Jun 2009
PSA/Prostate screening
Dr. Otis W. Brawley - Chief Medical Officer, ASCO
PSA/Prostate screening ( Dr. Otis W. Brawley - Chief Medical Officer, ASCO )
25 Jun 2009
Cancer prevention strategies
Professor Peter Boyle, International Prevention Research Institute
Cancer prevention strategies ( Professor Peter Boyle, International Prevention Research Institute )
25 Jun 2009
Zoledronic acid for treament of prostate cancer
Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals
Zoledronic acid for treament of prostate cancer ( Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals )
25 Jun 2009
ASCO: Patient accrual in clinical trials
Steven K. Cheng, PhD - Oregon Health and Science University, Oregan, USA
ASCO: Patient accrual in clinical trials ( Steven K. Cheng, PhD - Oregon Health and Science University, Oregan, USA )
22 Jun 2009
ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash
Dr. Edith Mitchell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash ( Dr. Edith Mitchell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA )
22 Jun 2009
ASCO: Impact of common antidepressants on tamoxifen effectiveness
Dr. Vincent O. Dezentjé - Leiden University Medical Center, Leiden, The Netherla...
ASCO: Impact of common antidepressants on tamoxifen effectiveness ( Dr. Vincent O. Dezentjé - Leiden University Medical Center, Leiden, The Netherlands )
18 Jun 2009
ASCO: Oxaliplatin does not improve outcomes for rectal cancer
Dr. Carlo Aschele - E.O. Ospedali Galliera, Italy
ASCO: Oxaliplatin does not improve outcomes for rectal cancer ( Dr. Carlo Aschele - E.O. Ospedali Galliera, Italy )
18 Jun 2009
ASCO: Pemetrexed extends survival as maintenance therapy
Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA
ASCO: Pemetrexed extends survival as maintenance therapy ( Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA )
18 Jun 2009
ASCO: Trial compares common adjuvant treatments for pancreatic cancer
Dr. John Neoptolemos - University of Liverpool, Liverpool, UK
ASCO: Trial compares common adjuvant treatments for pancreatic cancer ( Dr. John Neoptolemos - University of Liverpool, Liverpool, UK )
18 Jun 2009
ASCO: Surgery unnecessary for majority of patients with advanced colorectal canc...
Dr. Philip B. Paty - Memorial Sloan-Kettering Cancer Center, New York, USA
ASCO: Surgery unnecessary for majority of patients with advanced colorectal cancer ( Dr. Philip B. Paty - Memorial Sloan-Kettering Cancer Center, New York, USA )
18 Jun 2009
ASCO: Lung cancer screening by low-dose computed tomography results in high rate...
Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, US...
ASCO: Lung cancer screening by low-dose computed tomography results in high rate of false positives ( Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, USA )
18 Jun 2009
ASCO: Low rates of screening among childhood cancer survivors
Dr. Paul Nathan - Hospital for Sick Children, Toronto, Canada
ASCO: Low rates of screening among childhood cancer survivors ( Dr. Paul Nathan - Hospital for Sick Children, Toronto, Canada )
18 Jun 2009
ASCO: Childhood cancer survivors at risk of post-traumatic stress disorder
Dr. Margaret Stuber - Los Angeles David Geffen School of Medicine, Los Angeles,...
ASCO: Childhood cancer survivors at risk of post-traumatic stress disorder ( Dr.  Margaret Stuber - Los Angeles David Geffen School of Medicine, Los Angeles, California, USA )
18 Jun 2009
ASCO: Maintenance therapy for NSCLC
Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, US...
ASCO: Maintenance therapy for NSCLC ( Dr.  Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA )
18 Jun 2009
ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-...
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital,...
ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer ( Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US )
17 Jun 2009
ASCO: Experimental targeted therapy improves progression-free survival for advan...
Dr Roy Herbst, M.D. Anderson Cancer Center, Houston, US
ASCO: Experimental targeted therapy improves progression-free survival for advanced NSCLC ( Dr Roy Herbst, M.D. Anderson Cancer Center, Houston, US )
17 Jun 2009
Oestrogen and progestin therapy increases NSCLC risk
Dr Rowan Chlebowski - Harbor-UCLA Medical Center, Los Angeles, US
Oestrogen and progestin therapy increases NSCLC risk ( Dr Rowan Chlebowski - Harbor-UCLA Medical Center, Los Angeles, US )
17 Jun 2009
Results of the new Cetuximab studies in mCRC, from ASCO 2008
Professor Eric Van Cutsem
Results of the new Cetuximab studies in mCRC, from ASCO 2008 ( Professor Eric Van Cutsem )
28 Nov 2008
Cetuximab and docetaxal for squamous cell cancer of the head and neck, from ASCO...
Professor Jan B. Vermorken
Cetuximab and docetaxal for squamous cell cancer of the head and neck, from ASCO 2008 ( Professor Jan B. Vermorken )
27 Nov 2008
Cetuximab for metastatic colorectal cancer (mCRC), from ASCO 2008
Professor Carsten Bokemeyer
Cetuximab for metastatic colorectal cancer (mCRC), from ASCO 2008 ( Professor Carsten Bokemeyer )
27 Nov 2008
Cetuximab for NSCLC, from ASCO 2008
Professor Nicholas Thatcher
Cetuximab for NSCLC, from ASCO 2008 ( Professor Nicholas Thatcher )
27 Nov 2008
Cetuximab for NSCLC, from ASCO 2008
Professor Robert Pirker
Cetuximab for NSCLC, from ASCO 2008 ( Professor Robert Pirker )
27 Nov 2008